AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02347033 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy
Description: CBT will consist of 14 (+ / - 2) weekly 50-minute sessions and will cover 6 treatment modules: psychoeducation and worry awareness training; re-evaluation of the usefulness of worry; uncertainty recognition and behavioural exposure; problem-solving training; written exposure; and relapse prevention.~Sessions will be digitally recorded and a random 10% assessed for quality (fidelity to the manual and therapist competence) by an independent external assessor according to pre-specified criteria. Patient consent for this will be obtained as part of obtaining informed consent.
Study NCT00338364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAT
Description: Coping and Distraction Intervention
Study NCT02913729 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: partial breast irradiation
Description: irradiation
Study NCT02913729 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: partial breast irradiation
Description: irradiation
Study NCT01138579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FBTA05
Study NCT04496063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Intravenous induction (6mg/kg) followed by Ustekinumab subcutaneous 90mg every 8 weeks
Study NCT04496063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous followed by Placebo subcutaneous every 8 weeks
Study NCT01560689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide/formoterol
Description: 800 µg/j twice a day, every day
Study NCT01560689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice a day, every day
Study NCT04066790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib 400 mg taken orally everyday, every 3 weeks, for 4 cycles.
Study NCT04066790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Nab-paclitaxel 100mg/m2 by intravenous (IV) infusion on day1, day8 and day15, every 3 weeks, for 4 cycles.
Study NCT04066790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-Paclitaxel
Description: Nab-paclitaxel 100mg/m2 by intravenous (IV) infusion on day1, day8 and day15, every 3 weeks, for 4 cycles.
Study NCT04066790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 9, followed by 6 mg/kg for remaining cycles till completion of 1 year trastuzumab
Study NCT04066790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 9, followed by 6 mg/kg for remaining cycles till completion of 1 year trastuzumab
Study NCT04066790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC chemotherapy
Description: epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks 4 cycles (Cycles 5-8)
Study NCT04066790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC chemotherapy
Description: epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks 4 cycles (Cycles 5-8)
Study NCT04066790 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
Study NCT04066790 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
Study NCT00046085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Family Education
Description: Families were provided with private, secure access to the website, which features family-to-family chat capabilities, video lectures on the management of schizophrenia, written materials on important issues in schizophrenia management, professionally facilitated online discussions of the material, and additional resource links.
Study NCT00046085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Customary care
Description: Participants received care as usual.
Study NCT00046085 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Customary care
Description: Participants received care as usual.
Study NCT01487031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Patients randomized to receive music therapy will receive 2 sessions of live music therapy, at least 48 hours apart, from a Music Therapist-Board Certified (MT-BC, certified through the Certification Board for Music Therapists) in their room
Study NCT01487031 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No music therapy
Description: Those patients randomized to standard therapy (no music therapy) are allowed to listen to music; however they will not receive interactive music therapy from a certified therapist.
Study NCT03752099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERU-111
Description: VERU-111
Study NCT01087931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Single application of 10ml of bupivacaine 0.5% into the iliac crest bone harvest surgical site.
Study NCT01087931 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline 0.9%, 10ml, single application directly into iliac crest bone harvest surgical site.
Study NCT03706339 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline arm group
Description: 110 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the placental bed during Cesarean section
Study NCT03706339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous tranexamic acid
Description: 1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the pelvic bed during cesarean section
Study NCT03706339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid
Description: 2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 120 ml normal saline applied on the pelvic bed during cesarean section plus110 ml normal saline IV just before skin incision
Study NCT01207726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC
Study NCT01207726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO
Study NCT01207726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02623881 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical pessary
Description: Arabin (cervical pessary) will be inserted at 16-22 weeks and removed at 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
Study NCT02623881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal progesterone
Description: Vaginal progesterone (Cyclogest 400 mg) once a day will be used, from 16-22 to 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
Study NCT00459160 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative Hypotensive Resuscitation
Description: Patients will have a target minimum MAP of 50 for the case
Study NCT01091753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valsaltan, amlodipine
Description: nti hypertensive medication time (nocturnal administration vs morning administration
Study NCT01091753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsaltan, amlodipine
Description: nti hypertensive medication time (nocturnal administration vs morning administration
Study NCT01673568 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ETO garments
Description: patients wearing abdominal binder for 7 days postoperatively
Study NCT03090815 — intervention group
Intervention type: GENETIC
Intervention: Sequencing of ctDNA in plasma
Description: Sequencing of ctDNA in plasma
Study NCT03740997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optison
Description: Optison is administered intravenously
Study NCT02496520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cells
Description: vaccines with dendritic cells pulsed with tumor lysate
Study NCT02496520 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery as needed by the patient´s tumor and stage
Study NCT02496520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy as needed by the patient´s tumor and stage
Study NCT02496520 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy as needed by the patient´s tumor and stage
Study NCT02577757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI
Study NCT02577757 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Description: MRI
Study NCT03765411 — intervention group
Intervention type: PROCEDURE
Intervention: Proctectomy
Description: Resection of the rectum
Study NCT04823715 — intervention group
Intervention type: OTHER
Intervention: TACE + hypofractionated EBRT
Description: One cure of doxorubicin or DC Beads transarterial chemoembolization by a highly experienced interventional radiologist, followed 1 to 4 weeks later by hypofractionated external beam radiation therapy up to a total dose of 45-60 Gy, 3 Gy per fraction, 5 fractions per week, for an overall treatment time of 3 to 4 weeks.
Study NCT04823715 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical resection
Description: Surgical resection by open-laparotomy or laparoscopy of hepatocellular carcinoma by a highly experienced liver surgeon
Study NCT02020629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Description: Lixisenatide is given for 6 weeks whereafter a hypoglycemia clamp is undertaken
Study NCT00888433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Denervation (Symplicity® Renal Denervation System)
Description: Catheter-based renal denervation
Study NCT00755703 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic Influenza Vaccine
Description: Undetermined
Study NCT00755703 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04237766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: The intervention will consist of the visualization of the movement through the Mirror Therapy application, or through the reproduction of an immersive 360º video emitted on a mobile device and visualized with virtual reality glasses.~The movements observed with both technologies will be the same. The knee extension and dorsal ankle flexion movements (quadriceps and triceps sural), together with the elbow flexion (elbow flexors) will be the movements to be performed, based on their functional need (ambulation and feeding, respectively).
Study NCT00604812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan benzoate (5 mg)
Description: A single dose of rizatriptan 5 mg administered on Day 1.
Study NCT00604812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan benzoate (10 mg)
Description: A single dose of rizatriptan 10 mg administered on Day 1.
Study NCT00604812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rizatriptan 5 mg Placebo
Description: A single dose of rizatriptan 5 mg placebo administered on Day 1.
Study NCT00604812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rizatriptan 10 mg Placebo
Description: A single dose of rizatriptan 10 mg placebo administered on Day 1.
Study NCT00692978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate_1.5
Description: Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 1.5 micros, inhaled
Study NCT00692978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate_1.5
Description: Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 1.5 micros, inhaled
Study NCT00692978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate_3
Description: Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 3.0 microns, inhaled
Study NCT00692978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate_3
Description: Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 3.0 microns, inhaled
Study NCT00692978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate_6
Description: Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 6.0 microns, inhaled
Study NCT00692978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate_6
Description: Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 6.0 microns, inhaled
Study NCT00692978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP From Active 250 ug MDI Inhaler
Description: Monodisperse aerosols inhaled of Fluticasone Propionate at 250micrograms dose with active MDI inhaler
Study NCT00692978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP From Active 250 ug MDI Inhaler
Description: Monodisperse aerosols inhaled of Fluticasone Propionate at 250micrograms dose with active MDI inhaler
Study NCT01919710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHSA/GCSF
Description: for treatment of neutropenia
Study NCT01165645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir
Description: Given orally
Study NCT01165645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Given orally
Study NCT01165645 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies
Study NCT01165645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT01165645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies
Study NCT01165645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04362410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: Tezepelumab
Description: Tezepelumab single dose subcutaneously injection.
Study NCT04362410 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo single dose subcutaneously injection.
Study NCT00634010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 15 mg oral every 12 Hours; additional capsules taken every 2 hours as needed.
Study NCT00634010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: 5 mg orally every 12 hours; additional capsules every 2 hours as needed.
Study NCT02318823 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Beer (alcoholic)
Description: Beer (individually calculated amount aiming to achieve a blood-alcohol-centration of 0.4g/kg)
Study NCT02318823 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo (non-alcoholic beer)
Description: Non-alcoholic beer serves as Placebo.
Study NCT01658098 — intervention group
Intervention type: BEHAVIORAL
Intervention: edinburgh postpartum depression scale questionary
Description: the investigators will apply the qusetionary one time only in the period of time described previously
Study NCT01638117 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PAC14028-Vehicle
Description: PAC-14028 Cream Vehicle, Daily for up to 21 days
Study NCT01638117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC14028-0.1
Description: PAC-14028 Cream, 0.1%, Daily for up to 21 days
Study NCT01638117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC14028-0.3
Description: PAC-14028 Cream, 0.3%, Daily for up to 21 days
Study NCT01638117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC14028-1.0
Description: PAC-14028 Cream, 1%, Daily for up to 21 days
Study NCT01638117 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline, Daily for up to 21 days
Study NCT01638117 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive
Description: Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
Study NCT02618954 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Articular ultrasound
Description: (Device : Ultrasound) : Articular ultrasound of the Disease Activity Score (DAS) 28 articular joint
Study NCT01365143 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Radical Prostatectomy
Description: Robotic assisted radical prostatectomy
Study NCT01365143 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Radical Prostatectomy
Description: Open radical prostatectomy
Study NCT03061630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: D1.8.15 : GEMCITABINE 1000MG/M2
Study NCT03061630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: D1: CISPLATIN 60G/M2
Study NCT03124095 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined exercise Group
Description: The subjects of the combined training group will undergo the intervention three times a week for eight weeks. The combined group will carry out both resistance and aerobic exercises in the same session. The resistance training will be comprised by ten exercises which will alternate body segments with maximum repetitions in the first set and the lower limit of the repetitions interval in the next sets. Along the training, the number of series will be increased whereas the number of repetitions will be decreased. The intensity of the aerobic exercises will be based on the percentage of the heart rate of the anaerobic threshold on the first weeks and on the speed of the anaerobic and aerobic threshold on the last weeks
Study NCT02308826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Turtle Program
Study NCT02308826 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cool Little Kids
Study NCT03178929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Adenosyl Methionine
Description: 2000mg, po
Study NCT03916848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Micro-Macro SEEG Electrodes
Description: The novel combined micro-macro electrodes will then be used during the surgical implantation procedure. The use of these novel electrodes will not change the surgical procedure, which is conducted using robotic assistance to ensure optimal accuracy. The macro electrode recordings will be used for routine clinical analysis and the duration of recording and subsequent analysis of the recordings will not be affected by the micro electrode data captured for research purposes. The clinical SEEG also involves electrical stimulation of the brain which will not be affected by the study.
Study NCT00447759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200-400mg daily in divided doses
Study NCT00447759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: prescribed medication taken orally
Study NCT04607525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: On the scheduled time of operation, the head nurse opened each envelope just before surgery, prepared the infusion solution and handled it to the anesthesiologist who was blinded to the solution. He was then determined for collecting perioperative data.~Group D: Patients received 0.5 µg/kg/h of Dexmedetomidine. Dexmedetomidine dosage was diluted in 50 ml syringe of normal saline Group C: Patients received equal volume and rate of normal saline as Group D.~This dosing regimen was in accordance with existing guidelines \[5\] \[6\] \[7\].
Study NCT04607525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: On the scheduled time of operation, the head nurse opened each envelope just before surgery, prepared the infusion solution and handled it to the anesthesiologist who was blinded to the solution. He was then determined for collecting perioperative data.~Group C: Patients received equal volume and rate of normal saline as Group D.
Study NCT02582723 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High protein/high fat hard cheese
Description: Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
Study NCT02582723 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High protein/low fat hard cheese
Description: Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.